Roche FY25 Results Climb, Lifts Dividend; Sees Growth In FY26

Roche reported fiscal 2025 IFRS net income of CHF 13.80 billion, up 50% year‑over‑year (IFRS net income attributable to shareholders CHF 12.88 billion, CHF 16.04/share), while Core earnings were CHF 15.62 billion (CHF 19.46/share), up 4%; core operating profit rose 5% to CHF 21.83 billion and group sales reached CHF 61.52 billion (+2% reported, +7% at CER). Pharmaceuticals sales grew ~3% led by Phesgo, Xolair, Ocrevus, Hemlibra and Vabysmo, while Diagnostics fell ~3% amid Chinese pricing reforms; Q4 sales rose 8%. The board proposed raising the dividend to CHF 9.80/share and guided fiscal 2026 to mid single‑digit sales growth and high single‑digit core EPS growth at constant exchange rates, signaling continued shareholder returns and steady operational momentum.

Analysis

Market structure: Roche (RHHBY/ROG) emerges as a relative winner — Pharmaceuticals growth (Phesgo, Ocrevus, Hemlibra, Vabysmo) offsets Diagnostics China headwinds, implying durable pricing power in specialty meds and near-term margin pressure in diagnostics. Expect mid-single-digit group sales growth at CER in 2026 and core EPS high-single-digit guidance to re-rate the equity versus pure diagnostics peers; investors should model ~5–7% organic revenue growth and 100–200 bps margin expansion from pharma mix over 12 months. Cross-asset: higher dividends in CHF increase Swiss cash inflows and marginally support CHF vs USD/EUR; Swiss sovereign yields could see mild compression if flows persist.

Risk assessment: Tail risks include China pricing reforms broadening to other EM markets, accelerated biosimilar entry against key biologics, or a major Phase III failure — each could knock 15–30% off mid-term cash flows. Time buckets: immediate (days) — muted volatility on earnings beat; short-term (weeks–months) — sentiment around diagnostics exposure and FX; long-term (quarters–years) — patent expiries and competitive launches. Hidden dependencies: Roche’s diagnostics recovery hinges on pathology/molecular backlogs and China reimbursement reversals; reimbursement risk is correlated with EM macro weakness. Key catalysts: H1 2026 sales cadence, regulatory updates on biosimilars, and China pricing policy developments over next 60–180 days.

Trade implications: Favor asymmetric exposure to Roche equity and income strategies rather than pure diagnostics names. Direct play is a modest long in RHHBY with covered-call overlays to harvest the higher CHF dividend; pair-trade long Roche vs short a diagnostics-heavy peer hedges China/pricing risk. Use 9–18 month calls (LEAPS) for optionality; sell 3–6 month 5–10% OTM calls to boost yield. Entry: initiate within 2–4 weeks on any <5% pullback; add into 8–12% dips; target 12-month total return 12–18% with 10% stop-loss.

Contrarian angle: The market may underprice Roche’s pharma resilience and overprice diagnostics-as-a-permanent-drain narrative — last year’s impairments create a favorable base effect for FY25/FY26 comparables. Consensus misses potential incremental dividend-driven demand from income funds and insurers in CHF, which could compress free-float and lift the multiple if core EPS meets guidance. Conversely, if China expands aggressive price cuts across diagnostics, Roche’s diagnostics could lag peers and force margin re-forecasting; that risk is non-linear and justifies the pair-hedge.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Roche (RHHBY / ROG) within 2–4 weeks, targeting a 12-month total return of 12–18%; add on any 8–12% drawdown, and set a stop-loss at 10% below entry.
• Implement a covered-call overlay on 50–75% of the long position: sell 3–6 month calls 5–10% OTM to capture enhanced yield from the raised CHF dividend while retaining upside exposure.
• Execute a relative-value pair trade: long Roche (2% notional) vs short Siemens Healthineers ADR (SMMNY) (1.5% notional) to hedge China diagnostics/pricing risk; rebalance or close if spread moves >5% in 3 months.
• Buy 9–18 month RHHBY call options (notional ~30% of the equity position) to capture upside optionality around FY2026 catalysts (sales cadence, biosimilar/regulatory news); prefer defined-risk call spreads if volatility premium is elevated.